Stockreport

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals, Inc.  (EYPT) 
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF – Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., Oct. 24, 2024 (GLO [Read more]